COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease -
-
-
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain
Dépôt du Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel et du « Form 20-F » américain par Sanofi. Consultation en ligne disponible -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Sanofi and Teva's duvakitug phase 2b maintenance data show durable efficacy in ulcerative colitis and Crohn's disease. Results reinforce ongoing phase 3 programs in UC and CD
